Angel Rodis, MD
Critical Care Medicine · Marlton, NJNPI 1417947094
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by GSK at 24.4% of the total. 2025 is the largest year on record at $2,103, 7.8 times the $271 reported in 2019.
Across 210 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$764
- Regeneron Healthcare Solutions, Inc.$280
- Jazz Pharmaceuticals Inc.$278
- Sanofi$221
- Takeda Pharmaceuticals U.S.A., Inc.$205
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,26798%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 55 | $1,066 |
| AstraZeneca | 32 | $764 |
| Regeneron Healthcare Solutions, Inc. | 10 | $280 |
| Jazz Pharmaceuticals Inc. | 11 | $278 |
| Sanofi | 12 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $205 |
| ANI Pharmaceuticals, Inc. | 8 | $149 |
| Verona Pharma, Inc. | 9 | $147 |
| Harmony Biosciences LLC | 7 | $131 |
| Pulmonx Corporation | 1 | $110 |
| Amgen | 6 | $102 |
| Inari Medical, Inc. | 2 | $101 |
| Insmed, Inc. | 5 | $84 |
| Vapotherm Inc | 2 | $81 |
| Grifols USA, LLC | 4 | $65 |
| Lilly USA, LLC | 4 | $64 |
| Genentech USA, Inc. | 4 | $61 |
| Philips North America LLC | 3 | $51 |
| AbbVie | 3 | $50 |
| Actelion Pharmaceuticals US, Inc. | 3 | $46 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $42 |
| Boehringer Ingelheim | 2 | $41 |
| Novartis | 3 | $40 |
| United Therapeutics Corporation | 2 | $37 |
| Bayer | 2 | $34 |
| Boston Scientific | 1 | $24 |
| Ceribell, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| Circassia Inc. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$125
- NUCALA$122
- CHARTIS CATHETER$110
- ZEPHYR DELIVERY CATHETER$110
- ZEPHYR ENDOBRONCHIAL VALVE$110
- PULMONX CHARTIS TABLET CONSOLE$110
- BREZTRI$104
- AIRSUPRA$104
- TEZSPIRE$104
- FASENRA$104
- DUPIXENT$101
How this compares
$4,366 in reported general payments places this provider in the 80th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EsbrietPirfenidone | 12 | $122,659 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 149 | $122,525 |
| Breo ElliptaFluticasone/Vilanterol | 213 | $121,011 |
| Dupixent PenDupilumab | 14 | $56,605 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $45,686 |
| Spiriva HandihalerTiotropium Bromide | 41 | $30,351 |
| Spiriva RespimatTiotropium Bromide | 28 | $24,455 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 152 | $22,958 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $17,368 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $16,802 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 385 | $14,109 |
| EliquisApixaban | 17 | $11,225 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $10,569 |
| Tadalafil | 13 | $10,361 |
| Advair DiskusFluticasone Propion/Salmeterol | 25 | $7,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,066 | $309,771481 claims |
| Genentech USA, Inc.Esbriet | $61 | $122,65912 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $764 | $27,37166 claims |
| Boehringer IngelheimSpiriva Respimat | $41 | $24,45528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Marlton
- Neha VagadiaMarlton$31K
- Syed RiazMarlton$12K
- Aaron CrookshankMarlton$8K
- Emilio MazzaMarlton$7K
- Eric SztejmanMarlton$6K
- Jonathan GalliMarlton$5K
- Rohit MalikMarlton$5K
- Andrew SchiffMarlton$4K
- Roman KrolMarlton$4K
- Brian JaffeMarlton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.